Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Enliven Therapeutics, Inc. has initiated an underwritten public offering of $200 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $30 million more [1][2]. Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics aimed at improving survival and overall well-being through precision oncology [5]. - The company is based in Boulder, Colorado, and aims to address unmet medical needs with potentially first-in-class or best-in-class therapies [5]. Offering Details - The offering is being conducted under a Registration Statement on Form S-3, which has been declared effective by the SEC [3]. - The offering includes common stock and pre-funded warrants, with the final terms subject to market conditions [1][3]. - Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are acting as joint book-running managers for the offering, with LifeSci Capital as the lead manager [2].